J&J Covid vaccine produces strong immune response in early trial
The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed.
Full Article
J&J Covid vaccine produces strong immune response in early trial
Khaleej Times
0 shares
1 views
You might like
Related news coverage
-
Mumbai: Clinical trial of COVID-19 vaccine begins at KEM, Nair hospitals
Mid-Day
-
Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial
Indian Express
-
Covid: J&J vaccine shows strong immune response
IndiaTimes
-
Covid vaccine: Trial of new coronavirus vaccine starts in UK
BBC Local News
Advertisement
More coverage
Coronavirus Vaccines: R&D Landscape – Analysis
Eurasia Review
Scientists edge closer to develop a vaccine against the SARS-CoV-2 corona virus and Indian pharmaceutical companies are in front..
-
Kazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphoma
Proactive Investors
-
NA Proactive news snapshot: IEC Electronics, Innocan Pharma, Ion Energy, Alchemist Mining UPDATE ...
Proactive Investors
-
The Latest: WHO scientist: Trial suspension a 'wake-up call'
SeattlePI.com
-
Biopharmaceuticals battling COVID-19 pandemic to connect with investors via Proactive One2One Investor Forum on September 10
Proactive Investors